Cognition Therapeutics Q3 net loss narrows to $4.9M; secures $30M offering for zervimesine development

COGNITION THERAPEUTICS INC

2025-Q3 EPS reported -$0.30

Net loss of $4.9M ($0.06/shr) in Q3 2025 vs $9.9M loss ($0.25/shr) in Q3 2024.
Cash, equivalents & restricted cash $39.8M; plus $36.3M in NIH grant funds; runway into Q2 2027.
Closed $30M registered direct offering of 14.7M shares to institutional investors.
FDA aligned on registrational path for zervimesine (CT1812) in Alzheimer's disease.
Phase 2 START study >75% enrolled; expanded access program for dementia with Lewy bodies ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.